SRD5A2 and metabolic dysfunction-associated steatohepatitis: SRD5A2 mRNA expression was significantly decreased in NASH (dCT NASH 13.3±0.01 vs 10±0.01, p<0.01 NASH vs control), Figure 3B and GRα mRNA expression was significantly increased in NASH (dCT NASH 10.4±0.3 vs 11.7±0.3, p<0.05 NASH vs control), Figure 3C).